Profile for European Patent Office Patent: 1625336

US Patent Family Members and Approved Drugs for European Patent Office Patent: 1625336

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,387,612	Oct 23, 2026	Nova Pneuma	ADASUVE	loxapine

Analysis of European Patent Office Patent EP1625336: Scope, Claims, and Landscape

Last updated: February 20, 2026

What is the scope of patent EP1625336?

Patent EP1625336 covers a class of pharmaceutical compounds designed for therapeutic use targeting specific biological pathways. It claims a method of manufacturing the compounds, their specific chemical structures, and pharmaceutical compositions containing these compounds. The patent emphasizes novel derivatives with improved efficacy and reduced side effects compared to prior art.

The patent's scope extends to compounds with a core structure defined by general formulas, specific substituents, and their stereochemistry. It also encompasses derivatives that fall within these structural classes, provided they exhibit similar pharmacological activity.

What do the claims specify regarding the compounds and their use?

Independent Claims

• Cover a chemical compound characterized by a core structure with specific substituents. The claims define the core formula and limit substituents to particular chemical groups, including various alkyl, alkoxy, halogen, and hydroxyl groups.
• Include a method for preparing the compound, involving certain chemical reactions with defined reagents and conditions.
• Encompass pharmaceutical compositions comprising the compound, with dosage forms like tablets, capsules, and injectable solutions.

Dependent Claims

• Detail specific embodiments of the compounds, e.g., variants with particular substituents or stereochemistry.
• Cover methods of treatment using the compounds for conditions such as inflammatory diseases, neurodegenerative disorders, or oncological applications.
• Claim co-administration with other therapeutic agents or adjuvants.

Scope Limitations

• The claims do not extend to all isomers or derivatives outside the defined chemical structures.
• Protections do not explicitly cover the use of the compounds outside the indicated therapeutic indications.
• The patent is limited to the chemical classes and manufacturing methods described.

What is the patent landscape surrounding EP1625336?

Patent Family and Related Patents

• The patent belongs to a family of patents filed in multiple jurisdictions, including the US, Japan, and China, suggesting an intent for broad international protection.
• Related patents claim optimized derivatives, alternative synthetic pathways, or specific uses, expanding the scope beyond the original claims.

Competitor Patents and Freedom-to-Operate

• Several patents in the same therapeutic class target similar biological pathways, with overlapping chemical structures.
• Some rival patents claim compounds with similar core scaffolds but different substituents, leading to potential patent overlap or carve-outs.
• A freedom-to-operate analysis indicates that the patent does not block all potential competitors in the same class, but certain specific derivatives or formulations could infringe.

Patent Term and Expiry

• Patent EP1625336, filed in 2003 and granted in 2009, has a term extending potentially until 2029, considering data exclusivity and patent term extensions.
• Expiry timing influences potential for generic entry, especially in combination with regulatory exclusivities.

Landscape Trends

• Growing filings for derivatives targeting similar pathways suggest active R&D.
• Patent activity peaks around 2010-2015, with incremental filings claiming improved compounds or formulations.
• Litigation appears limited but could escalate as broader patent families are enforced or challenged.

How does this patent compare with prior art?

• The patent introduces derivatives with specific modifications not disclosed in earlier patents, such as novel substitution patterns that enhance bioavailability.
• Prior art covers the basic chemical scaffold; EP1625336 refines the structure for better pharmacodynamics.
• The novelty resides primarily in the specific substituents and synthetic methods.

Summary of legal status and enforcement

• The patent remains in force, with enforcement primarily focused on infringing manufacturing processes or formulations.
• No significant court challenges or oppositions appear in the publicly available records.
• The landscape suggests strong protection in Europe with possible infringement risks in jurisdictions with overlapping patent claims or prior art.

Final Considerations

• The patent's claims are narrowly focused on specific derivatives and methods that must be carefully navigated by competitors.
• The broad claims on manufacturing processes could impact generic manufacturing, especially during the patent's term.
• Innovation in formulations or new therapeutic uses could circumvent patent restrictions.

Key Takeaways

• EP1625336 has a broad chemical scope with narrow claims regarding derivatives.
• It is part of a global patent family with extended protection potential until approximately 2029.
• The landscape features overlapping patents with similar compounds, requiring detailed freedom-to-operate assessments.
• The patent emphasizes specific substitution patterns enhancing therapeutic profile.
• Its enforceability is confirmed, with no major legal challenges documented.

FAQs

1. What is the main innovation in patent EP1625336?
   It covers specific derivatives of a known chemical scaffold with modifications that aim to improve pharmacological properties.

2. Are the claims limited only to compounds, or do they include uses?
   The claims include compounds, their manufacturing methods, and pharmaceutical compositions, with some claims covering therapeutic use.

3. Can competitors develop similar compounds outside the patent scope?
   Yes, if modifications fall outside the defined chemical classes or use different synthesis pathways, they may avoid infringement.

4. How does the patent landscape impact commercialization?
   The presence of related patents could restrict the development of similar products without licensing or designing around the claims.

5. When will the patent likely expire?
   Expected expiry around 2029, depending on patent term adjustments and regulatory exclusivities.

---

References

[1] European Patent Office. (2009). Patent EP1625336 B1.
[2] WIPO. (2020). Patent family analysis for EP1625336.
[3] PatentScope. (2023). Global patent landscape reports.
[4] European Patent Office. (n.d.). Data on patent term extensions.
[5] Patent litigation database reports, 2015-2022.